Navigation Links
15 top medical organizations agree on hormone therapy use
Date:7/9/2012

(July 9, 2012) After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits. The new joint statement, prepared by The North American Menopause Society (NAMS), the American Society for Reproductive Medicine (ASRM), and The Endocrine Society, concludes that hormone therapy is still an acceptable treatment for menopausal symptoms. This statement has been endorsed by 12 other leading organizations in women's health.

The purpose of this statement is to reassure women and their providers that hormone therapy is acceptable and relatively safe for healthy, symptomatic, recently postmenopausal women. Over the last 10 years, there has been a complete abandonment of hormone therapy in some settings accompanied by reluctance to treat women who would benefit from relief of their symptoms. As a result, some women have sought unproven alternative therapies.

"We believe that too many symptomatic women are missing out on the proven benefits of hormone therapy because the results of the WHI, which studied the long-term use of hormones to prevent chronic disease, were misinterpreted for women with menopausal symptoms" said Dr. Margery Gass, Executive Director for NAMS. "Women and clinicians are frustrated by the many conflicting recommendations. That's why we initiated this effort to bring these notable medical organizations together in agreement regarding the use of hormone therapy."

Roger Lobo, MD, Past President of the American Society for Reproductive Medicine added, "Physicians can help patients determine, based on their own particular characteristics and history, whether or not they are good candidates for hormone therapy and what type of HT will provide them the greatest relief at the lowest risk. A decade of research and analysis has shown us that the generalized conclusions of the WHI do not apply to younger women at the beginning of the menopausal transition."

"The results of the WHI and the conflicting reports that followed led many women to believe hormone therapy may not be a safe treatment for menopausal symptoms," said Janet E. Hall, MD, immediate Past President of The Endocrine Society. "We want women to know that there are options out there for relief of their menopausal symptoms. The level of risk depends on the individual, her health history, age, and the number of years since her menopause began."

When it comes to the safety and effectiveness of hormone therapy, one commonly heard lament is, "Even the experts don't agree." This statement was prepared to address this misperception by presenting evidence-based key concepts about hormone therapy to assist women and their clinicians in making informed decisions about use of hormone therapy when appropriate.

Major points of agreement among the societies include:

  • Hormone therapy is an acceptable option for the relatively young (up to age 59 or within 10 years of menopause) and healthy women who are bothered by moderate to severe menopausal symptoms. Individualization is key in the decision to use hormone therapy.
  • If women have only vaginal dryness or discomfort with intercourse, the preferred treatments are low doses of vaginal estrogen.
  • Women who still have a uterus need to take a progestogen (progesterone or a similar product) along with the estrogen to prevent cancer of the uterus. Women who have had their uterus removed can take estrogen alone.
  • Both estrogen therapy and estrogen with progestogen therapy increase the risk of blood clots in the legs and lungs, similar to birth control pills, patches, and rings. Although the risks of blood clots and stroke increase with either type of hormone therapy, the risk is rare in women ages 50-59.
  • An increased risk in breast cancer is seen with 5 or more years of continuous estrogen with progestogen therapy, possibly earlier. The risk decreases after hormone therapy is stopped.


'/>"/>
Contact: Carolyn Develen
carolyn@menopause.org
440-442-7657
The North American Menopause Society (NAMS)
Source:Eurekalert

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
3. CAM therapy combined with conventional medical care may improve treatment of lower back pain
4. Image share project gives patients and physicians anytime, anywhere access to medical images
5. Researchers determine vitamin D blood level for reducing major medical risks in older adults
6. Biomedical researchers receive Hartwell Foundation awards
7. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
8. Fitness in Middle Age Lowers Medical Costs Later: Study
9. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
10. Gene Tests May Not Drive Patients to More Medical Care
11. University studies and career expectations of medical students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim Jong-nam, ... nerve agents and the deadly use of chemical weapons. Many questions exist about the ... small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, ...
(Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
(Date:2/26/2017)... Overland Park, KS (PRWEB) , ... ... ... launch of StaffBridge sets a new technology standard in staffing, scheduling, and ... to manage, monitor, and predict activity throughout the entire staffing process. StaffBridge ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... (PD) in persons with a specific LRRK2 mutation, according to a study released ... studies have provided evidence of a link between pesticides and incidence of sporadic ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... tooth replacement options at his office, Antoine Dental Center. Currently, patients can get ... Some restrictions may apply, but patients can learn more about these offers by ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Medical information groups within the ... self-service capabilities to manage inquiries from external stakeholders ... New research from consulting leader Best Practices, LLC ... website portals where HCPs can sign on and ... many findings to emerge from the new study ...
(Date:2/24/2017)... -- Report analyzes the worldwide markets for Endodontic Supplies in ... US, Canada , Japan ... , Latin America , and Rest of ... 2015 through 2022. Also, a six-year historic analysis is provided ... primary and secondary research. Company profiles are primarily based on ...
(Date:2/24/2017)... -- Directors from Pharma To Market Pty Ltd and Ador Consulting Pte ... the founding of Pharma To Market Pte Ltd, based in ... to announce their expansion into Asia with ... The company are delighted to appoint Joelle Chia , former ... based entity. Joelle brings with her an extensive business ...
Breaking Medicine Technology: